Diarrhea-predominant irritable bowel syndrome
Conditions
Interventions
Saccharomyces boulardii intervention group:Enterol (Saccharomyces boulardii powder):
Manufacturer: BIOCODEX (France)
500mg twice a day, taken for four weeks.
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18 years or older and below 65 years diagnosed with IBS according to the Rome IV criteria. 2. Underwent colonoscopy at a tertiary hospital within 2 years prior to screening, with the examination report retained. 3. Able to comprehend and accept the study protocol, and voluntarily provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant individuals or those unable to practice effective contraception during the study period. 2. Require long-term use of immunosuppressants, glucocorticoids, opioids, antidepressants, or anxiolytics; or use of alcohol, illicit drugs, or other medications that could potentially interfere with the study. 3. Previous definitive diagnosis of organic gastrointestinal diseases, such as inflammatory bowel disease, intestinal tuberculosis, intestinal polyps (polyps < 0.5 cm may still be included), intestinal diverticula, intestinal tumors, etc.; or current coexisting conditions such as peptic ulcer or infectious diarrhea. 4. Systemic diseases that may affect gastrointestinal function, such as hyperthyroidism, diabetes, myasthenia gravis, etc. 5. Previous definitive diagnosis of diseases with symptoms similar to IBS, such as eosinophilic gastroenteritis, microscopic colitis (including collagenous colitis and lymphocytic colitis), lactose intolerance, or malabsorption syndrome. 6. History of gastrointestinal surgery (except appendectomy and intestinal polypectomy), such as cholecystectomy. 7. Presence of severe psychiatric disorders or language barriers, preventing adequate understanding of the study and provision of informed consent. 8. Any other condition considered by the investigator to make the subject unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate to treatment for IBS-D; | — |
Countries
China
Contacts
Public ContactXiaohua Hou
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed